Plumbagin may exert these antitumor effects by abrogating STAT3-PLK1-AKT signaling, which suggests that plumbagin may be a novel, promising anticancer agent for the treatment of ESCC. The gene discussed is AKT1; the disease is esophageal squamous cell carcinoma.